ECONOMY & WORK
MONEY 101
NEWS
PERSONAL FINANCE
NET WORTH
About Us Contact Us Privacy Policy Terms of Use DMCA Opt-out of personalized ads
© Copyright 2023 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.
MARKETREALIST.COM / ECONOMY & WORK

Take a Look at the Report That has Sparked a Debate Around Pricing of Pharmaceuticals

Other nations typically pay far less for medications, mostly because their governments often determine the cost.
PUBLISHED FEB 11, 2024
Cover Image Source: Drugs | Pexels | Photo by Pixabay
Cover Image Source: Drugs | Pexels | Photo by Pixabay

Senator Bernie Sanders' recent report exposing a glaring contrast in the prices of three major drugs between the United States and several other countries, has once again turned the spotlight toward the pharmaceutical industry. It has reignited a debate around the affordability of healthcare.

Image Source: Pexels|Photo by MART PRODUCTION
Image Source: Pexels | Photo by MART PRODUCTION

It sheds light on cases such as that of Bristol Myers Squibb’s Eliquis, a blood thinner reducing stroke risk, which has an annual list price of $7,100, but is priced at $940 in Japan, $900 in Canada, $770 in Germany, $760 in the UK, and $650 in France.

Moreover, Johnson & Johnson’s arthritis drug Stelara listed at $79,000 annually in the US, is priced at $30,000 in Germany; $20,000 in Canada; $16,000 in the UK; $14,000 in Japan; and $12,000 in France.

The growing need of healthcare and the industry has urged entrepreneurs to come up with new and helpful ideas|Pexels
Image Source: Healthcare fraud | Pexels

These disparities have fueled outrage, prompting Sanders to convene a hearing with the CEOs of the implicated drugmakers before the Senate Committee on Health, Education, Labor, and Pensions, which he chairs. This move, intended to hold the pharmaceutical giants accountable, highlights the urgency of addressing the issue. For the first time, Medicare is engaging in direct negotiations with drug manufacturers, targeting ten expensive medications, including Eliquis and Stelara.

Sanders is also hinting at the possibility of issuing the committee's first subpoenas in over 40 years to compel Johnson & Johnson and Merck executives to testify.

While the negotiation process doesn't factor in prices paid in other countries, it symbolizes a potential shift towards fairer pricing practices within the US. 

Image Source: andresr/Getty Images
Image Source: Photo by Andresr | Getty Images

The Biden administration, along with Sanders and other advocates, has long decried the gaping disparity between drug prices in the US and those in other developed nations. Former President Donald Trump also attempted to address this issue by advocating for a "most-favored-nation price" policy, aligning Medicare payments with those of other countries. However, such initiatives have faced opposition and challenges along the way.

Furthermore, list prices, which often dictate insurance premiums and out-of-pocket expenses, pose a significant financial burden, particularly for those without adequate coverage.

Drug makers fear that price negotiations could stifle innovation by undercutting profits. They contend that reduced revenue streams could hamper investment in research and development, potentially impeding the discovery of new life-saving medications. However, the Senator's report highlighted that in 2022, Johnson & Johnson and Bristol Myers Squibb allocated $17.8 billion and $12.7 billion, respectively, towards stock buybacks, dividends, and executive compensation.

In contrast, their investments in research and development amounted to $14.6 billion and $9.5 billion. However, Merck demonstrated a different approach by investing nearly double the amount in research and development compared to dividends and executive compensation. Critics counter this by adding that exorbitant profits, coupled with substantial spending on stock buybacks and executive compensation, suggest a prioritization of financial gain over genuine societal concerns.

Representative Image | Getty Images | Photo by Spencer Platt
Image Source: Getty Images | Photo by Spencer Platt

The staggering profits amassed by pharmaceutical companies, primarily in the US market, also raise questions about the ethics of prioritizing profit margins over patient access to essential medications. The contrasting difference in pricing further underscores the need for systemic reforms to ensure equitable access to healthcare for all.

MORE ON MARKET REALIST
Harvey seemed quite annoyed after the guest revealed her surprise and rightfully so.
5 hours ago
Both Rick and his son Corey had a lot of luaghs while talking about this item for obvious reasons.
7 hours ago
She was just happe to be with Drew Carey on stage, and perhaps did not expect such a big win.
9 hours ago
The segment started with a couple of people entering the stage wearing cakes over their heads.
10 hours ago
The valuation he asked for was as crazy as the outfit he wore, and the sharks said no.
12 hours ago
The contestant's answer had no lewd intention but Steve Harvey made sure it did.
1 day ago
Fans of the gameshow are known to be vocal about their needs and this was just an example of that.
1 day ago
The guest stood firm at what he wanted and Harrison was forced to raise his low-ball offer.
1 day ago
The contestant was confident in his abilities and he steered his team to an impressive win.
1 day ago
The sharks could not believe what they had just witnessed but it sure was entertaining.
2 days ago
The guest said that she wanted $15,000 but had to settle for just a couple grand.
2 days ago
Fans of the show were shocked she was not able to get it right after coming so close.
2 days ago
Corcoran was confident that the entrepreneur would take her deal but that was not the case.
3 days ago
The host's expressions upon seeing the answers on the board were absolutely priceless.
3 days ago
The guest was a friend of the Harrisons and he turned out to be quite the negotiator.
3 days ago
The guest had an item that was presumably made in the pre-1800s era, which made it valuable.
4 days ago
She had asked for $250,000 when she came and she walked away with close to $400,000.
5 days ago
The showrunners must have had a storm on their hands when they were called out.
5 days ago
Steve Harvey burst out laughing when he heard that answer, as was the case in much of the round.
5 days ago
The guest wanted more than $3,000 for the item but the expert crushed his hopes.
6 days ago